Dasan Pharmaceutical Co., Ltd.

Dasan Pharmaceutical Co. , Ltd. , based in South Korea, specializes in the development and production of pharmaceuticals and healthcare products, focusing on enhancing patient outcomes through innovative solutions. Founded in 1996 and headquartered in Asan-si, South Korea, Dasan Pharmaceutical Co.

, Ltd. focuses on producing a wide array of pharmaceuticals. The company has engaged in a significant funding round, raising KRW 13 billion in a PRE-IPO round on December 23, 2025, with investors including KB Securities and NH Investment & Securities. This funding contributes to the single deal they have undertaken, amounting to a total of KRW 13 billion raised.

Dasan Pharmaceutical Co. , Ltd. specializes in developing and manufacturing a wide range of pharmaceuticals and related healthcare products. Its offerings include prescription medications, over-the-counter drugs, and specialty treatments catering to various health conditions, including chronic diseases and acute illnesses.

The company aims to improve patient outcomes and quality of life, serving a customer base that includes healthcare providers like hospitals, clinics, pharmaceutical distributors, and retail pharmacies. Dasan Pharmaceutical distributes its products across key markets in Asia, Europe, and North America, addressing specific regional healthcare needs. Dasan Pharmaceutical Co. , Ltd.

generates revenue through direct sales to healthcare providers and partnerships with pharmaceutical wholesalers and distributors. Transactions typically involve bulk orders negotiated based on the volume and type of medications supplied. The company also engages in contractual agreements with hospitals for exclusive supply arrangements and may offer specialized pricing plans for flagship products tailored to B2B clients and direct consumers, thereby ensuring a balanced revenue stream across different healthcare market sectors. In December 2025, Dasan Pharmaceutical Co.

, Ltd. raised KRW 13 billion in pre-IPO funding, which will be utilized to enhance corporate value and expedite the company's entry into international markets. The company is strategically targeting expansion into new geographic regions, focusing on increasing its presence in underrepresented markets worldwide in the coming years.